Vertex passes neuropathic pain test, teeing up pivotal trials in pursuit of blockbuster opportunity
Vertex’s decision to double down on a pain program has delivered a phase 2 win. The biotech linked its NaV1.8 inhibitor VX-548 to statistically significant improvements in pain intensity in people with painful diabetic peripheral neuropathy (DPN), encouraging it to start planning a pivotal program.